Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

A Minute for my Kidneys

NCT07869849 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-11
Last updated
2026-10-13

Condition(s) studied

Chronic Kidney Diseases

Investigational drug(s) / intervention(s)

Dialysis

Dialysis: Dialysis for a patient with stage V chronic kidney disease

Study summary

The purpose of this study is to evaluate the effectiveness of the "One Minute for My Kidneys" program in reducing the time it takes for participants with stage V chronic kidney disease and other comorbidities to begin dialysis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 and ≤ 80; * Participants with stage V chronic kidney disease; * Participants with documented type 2 diabetes AND/OR documented glomerular disease (proteinuria \> 1 g/24 h) AND/OR diagnosed with heart failure as recognized by a cardiologist according to the criteria of the European Society of Cardiology; * Participants who have and agree to use an internet connection; * Participants who speak and understand French and are able to complete the questionnaires; * Participants who have been informed and have signed an informed consent form; * Participants covered by a social security program. Exclusion Criteria: * Inability to use the app (blindness, severe intellectual disability); * Life expectancy of less than 6 months, as determined by the investigator; * Significant noncompliance, as determined by the investigator; * Participants for whom, in the event of end-stage renal disease, palliative care would be chosen over dialysis or transplantation; * Women who are pregnant or may become pregnant (of childbearing age and not using effective contraception) or who are breastfeeding; * Persons under legal guardianship (under legal protection or deprived of liberty by judicial or administrative decision); * A person unable to understand the information related to the study (due to linguistic, psychological, cognitive, or other reasons); * A participant currently enrolled in another clinical trial or study, or who has participated in another clinical trial or study that could have affected their health status within the 6 months prior to enrollment.

Primary outcome measure(s)

  • Time to initiation of dialysis — Up to 24 months
    Time to initiation of dialysis (scheduled and unscheduled) for participants with stage V chronic kidney disease and one or more comorbidities.

Trial sites (1)

FacilityCityRegionStatus
Hôpital Privé La Louvière Lille France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07869849 on ClinicalTrials.gov ↗ ← All trials in France